{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Corbellari R"],"funding":["Swiss National Science Foundation","European Research Council"],"pagination":["859-871"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7611336"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(5)"],"pubmed_abstract":["IL15 is an immunostimulatory cytokine that holds promises for cancer therapy, but its performance (alone or as partner for fusion proteins) has often been limited by suboptimal accumulation in the tumor and very rapid clearance from circulation. Most recently, the Sushi Domain (SD, the shortest region of IL15 receptor α, capable of binding to IL15) has been fused to IL15-based anticancer products to increase its biological activity. Here, we describe two novel antibody fusion proteins (termed F8-F8-IL15 and F8-F8-SD-IL15), specific to the alternatively spliced EDA domain of fibronectin (a marker of tumor neoangiogenisis, expressed in the majority of solid and hematologic tumors, but absent in normal healthy tissues) and featuring the F8 antibody in single-chain diabody format (with a short"],"journal":["Molecular cancer therapeutics"],"pubmed_title":["A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis."],"pmcid":["PMC7611336"],"funding_grant_id":["182003","310030_182003/1","670603","310030"],"pubmed_authors":["Ongaro T","De Luca R","Villa A","Mock J","Neri D","Corbellari R","Stringhini M"],"additional_accession":[]},"is_claimable":false,"name":"A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis.","description":"IL15 is an immunostimulatory cytokine that holds promises for cancer therapy, but its performance (alone or as partner for fusion proteins) has often been limited by suboptimal accumulation in the tumor and very rapid clearance from circulation. Most recently, the Sushi Domain (SD, the shortest region of IL15 receptor α, capable of binding to IL15) has been fused to IL15-based anticancer products to increase its biological activity. Here, we describe two novel antibody fusion proteins (termed F8-F8-IL15 and F8-F8-SD-IL15), specific to the alternatively spliced EDA domain of fibronectin (a marker of tumor neoangiogenisis, expressed in the majority of solid and hematologic tumors, but absent in normal healthy tissues) and featuring the F8 antibody in single-chain diabody format (with a short","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2026-05-08T10:36:15.333Z","creation":"2022-02-09T08:01:08.542Z"},"accession":"S-EPMC7611336","cross_references":{"pubmed":["33632875"],"doi":["10.1158/1535-7163.MCT-20-0853","10.1158/1535-7163.mct-20-0853"]}}